A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Tedizolid (Primary) ; Tedizolid (Primary)
- Indications Gram-positive infections; Skin and soft tissue infections
- Focus Pharmacokinetics
- Sponsors Trius Therapeutics
- 23 Feb 2016 Results published in the Pediatric Infectious Disease Journal
- 19 Oct 2012 Results were presented at IDWeek in October 2012.
- 27 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.